Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML.
We studied the expression of gelatinase-A (MMP-2) and gelatinase-B (MMP-9) in bone marrow aspirates from 54 patients with leukaemia. Specific staining patterns for different leukaemia subtypes are described. Most intresting were findings in acute myeloid leukaemia (AML), where MMP-2 staining correlated strongly with prognosis. Three year event-free survival after conventional treatment for patients with MMP-2 positive blast cells was 82%, while all the conventionally treated patients with MMP-2 negative blasts relapsed within 13.5 months. After treatment with allogeneic bone marrow transplantation, 3-year event-free survivals were 100% and 80% for MMP-2 positive and negative patients respectively.
Kuittinen
O
O
Department of Oncology and Radiotherapy, Oulu University Hospital, Finland.
Savolainen
E R
ER
Koistinen
P
P
Turpeenniemi-Hujanen
T
T
D000208:Acute Disease; D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000201:enzymology; D007951:Leukemia, Myeloid / Q000201:enzymology* / Q000235:genetics / Q000401:mortality* / Q000473:pathology; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis*; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis*; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000201:enzymology; D011379:Prognosis
D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9